12:00 AM
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RPL554: Phase I data

A double-blind, U.K. Phase I trial in 21 healthy volunteers who were challenged with an inhaled irritant on day 6 showed that once-daily RPL554 for 6 days non-significantly reduced the proportion of neutrophil cells to total inflammatory cells in the sputum vs. placebo, but did significantly reduce the absolute number of neutrophils vs....

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >